Acute Repetitive Seizures Market

Global Acute Repetitive Seizures Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2029: The primary drivers expected to drive the global acute repetitive seizures market are growth in the frequency of clinical studies, greater focus on the development of novel medicines, and increase in the need for nasal aerosols for the diagnosis of epilepsy.

Global Acute Repetitive Seizures Market is valued at USD 559.03 Million in 2022 and expected to reach USD 7754.69 Million by 2029 with a CAGR of 45.6% over the forecast period.

Scope-

Acute recurrent seizure is a disorder that arises in people who have drug-resistant epilepsy. Cluster seizure, breakthrough seizure, seizure flurry, serial seizure, seizure cluster, or extended seizure are other names for it. The acute repetitive seizure is distinguished by the development of seizures at frequent periods, which might be hours or sometimes moments. The regularity with which these seizures develop is determined by the kind of epilepsy, including mesial temporal lobe epilepsy as well as the patient's features. Three catamenial seizures develop in women with mesial temporal lobes during two premenstrual days. Rectal gels as well as nasal sprays are employed to treat acute repeated seizures.

With escalating COVID-19 cases globally, significantly increasing hospital admittance and readmission costs, and increased need for telehealth and telecare solutions for distant patient surveillance, the coronavirus outbreak has had a significant influence on the international healthcare business. Moreover, increasing focus on accelerated COVID-19 diagnosing including RT-PCR test kits, enhanced government financing for vaccine innovation, strict regulations rules, and procedures for COVID-19 protection, and growing revenues of COVID-19 security machinery including N-95 masks, face protection, PPE kits, and cleansers have fueled recent income expansion in the worldwide pharma & healthcare sector.

The global Acute Repetitive Seizures market is segmented based on the offering, security, threat type, solution, end-use, and region & country level. Based on offering, the global Acute Repetitive Seizures market is segmented into services and solutions. By security, the market is segmented into product type and end-use. By product type, the global Acute Repetitive Seizures market is segmented into NRL-1, USL-261, AZ-002, Diastat Rectal Gel, Others. By end-use, the global Acute Repetitive Seizures market is segmented into Biotechnology, Healthcare and Pharmaceuticals, and Others.

The regions covered in the global Acute Repetitive Seizures market report are North America, Europe, Asia-Pacific, Latin America, and the Rest of the World. On country level, the market of global Acute Repetitive Seizures is sub divided into the U.S., Mexico, Canada, the U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players-

Some major key players for the global Acute Repetitive Seizures market report cover prominent companies like -

• Alexza Pharmaceuticals
• Bausch Health
• Neurelis Inc.
• Pfizer Inc.
• Sanofi
• UCB S.A.
• Veriton Pharma
• Valeant Pharmaceuticals North America LLC
• Grupo Ferrer Internacional S.A.
• others

Segmentation-

By Product Type:

• NRL-1
• USL-261
• AZ-002
• Diastat Rectal Gel
• Others

By End-User:

• Biotechnology
• Healthcare and Pharmaceuticals
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Increasing innovation in healthcare medicine, growing healthcare spending, and increasing incidents of epilepsy are some of the major factors driving the market growth

The increasing number of clinical trials, greater focus on the launch of innovative medications, and strong demand for nasal decongestants for the therapy of epilepsy are all driving market development in the global acute repetitive seizures market. Moreover, the growing number of regulatory clearances and viable therapies in the market are expected to propel the acute repeated seizures industry throughout the projected period.

Furthermore, authorities are striving hard to minimize hospital visits and on-site treatment costs via ambulatory care models including home healthcare as well as hospitals in order to cut healthcare expenditures. Developing nations, including China, are rapidly adopting similar healthcare modifications, which are projected to propel the acute repeated seizures industry further in the coming years.

The global acute repetitive seizures market has grown owing to an increase in epilepsy cases, with around 3.4 million individuals dealing with the illness. Epilepsy affected around 470,000 adolescents and 3 million adults in the United States, according to the Centers for Disease Control and Prevention. The marketplace for acute repeated seizure therapy will grow as unmet needs for caregivers and patients develop. Constant study and development, as well as a continuous product portfolio, are among the primary elements expected to fuel industry growth.

Nevertheless, several hurdles are impeding the therapy marketplace for acute repeated seizures, including adverse medication responses and drug-induced seizures. These problems are impeding the development of the acute repeated seizure industry. The recurrent seizure industry is likely to be driven by reduced hospital stays advancements in treatment approaches, inexpensive medication costs, and healthcare coverage facilities.

North America is Expected to Capture a Major Share in the Global Acute Repetitive Seizures Market

North America had the largest share of the global acute repetitive seizures market over the forecast period. This increase may be attributed to an increase in the prevalence of neurological illnesses, current pharmacological releases, an increase in brain traumas, and a well-established healthcare framework. This tendency is projected to continue throughout North America over the forecast period. Furthermore, the acute repetitive seizures market in Europe is predicted to grow rapidly due to an increase in R&D spending in neurology, an increase in funding offered by the administration, and an increase in the need for epilepsy pharmaceuticals.

The Asia Pacific industry is also expected to grow rapidly due to rising healthcare spending in emerging nations including India and China. In this region, there is a significant deficit in the management of acute repetitive seizures. As a result, the market for anti-seizure medications in these emerging nations stimulates a shift in market potential away from the highly congested European as well as North American sectors and toward these countries.

News-

Pharmanovia launched license and supply agreement with Aquestive Therapeutics, Inc. for patented diazepam buccal film formulation

On September 28^th, 2022, Pharmanovia, a lifecycle management company, declared an exclusive license and supply contract with Aquestive Therapeutics, Inc. for its patented diazepam buccal film composition in the EU, Switzerland, the UK, and Norway, along with nations in the Middle East and North Africa (MENA) - several 48 markets. The US Food and Drug Administration (FDA) has awarded Aquestive Therapeutics tentative authorization for its diazepam buccal film for the acute therapy of intermittent, stereotypic incidents of common seizure exercise (i.e., acute repetitive seizures, seizure clusters) which are distinguishable from a patient's usual seizure sequence in patients with epilepsy 12 years of age or above.

CB declared a contract to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261)

On June 24^th, 2022, CB confirmed a contract to purchase the license to Proximagen's Midazolam Nasal Spray (USL261), an anti-epilepsy medicine (AED) established as a rescue therapy for individuals with epilepsy experiencing acute repeated seizures (ARS, also referred to as serial, recurring, or cluster seizures). USL2612 is a unique experimental midazolam formulation developed exclusively for intranasal administration without active inhaling. The United States Food and Medicine Administration (FDA) has awarded its orphan drug classification and fast-track designation, indicating the considerable unmet need for ARS rescue therapy.

US Food and Drug Administration extended shelf life of the first nasal spray accepted for the acute diagnosis of intermittent NAYZILAM

On February 22^th, 2022, NAYZILAM, the first nasal spray accepted for the acute diagnosis of intermittent, stereotypic incidents of common seizure activity (i.e., acute repetitive seizures, seizure clusters) which are distinguishable from a patient's customary seizure sequence in patient populations with epilepsy 12 years of age and or over, has had its shelf life lengthened from 12 to 24 months by the US Food and Drug Administration.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 559.03 Million
Base year considered	2021
Forecast Period CAGR %:	45.6%
Market Size Expected in 2029:	USD 7754.69 Million
Tables, Charts & Figures:	175
Pages	300
Companies	Alexza Pharmaceuticals, Bausch Health, Neurelis, Inc., Pfizer Inc., Sanofi, UCB S.A., Veriton Pharma, Valeant Pharmaceuticals North America LLC, and Grupo Ferrer Internacional S.A. among others.
Segments Covered	By Product Type, By End-User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa